Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: emricasan, nivocasan | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 11 Parkinson's papers of 1,799 | 0.67 |
| pathways Reactome | 22 pathways; mostly mitochondrial quality control | 1.00 |
No case: the score is under the bar. Receipt 6792
Sealed predictions
- CASP8 in dopamine neurons, braak+0.11 (p 0.777) → -0.20 (p 0.607)receipt 6798
Swarm cases
receipt 6798: CASP8 in dopamine neurons, braak
- power
- full sample +0.03 (p 0.915, n 18), 95% CI -0.45 to +0.49. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.02 (p 0.928, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.02 (p 0.942, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.16, sign flips 7; without severely affected donors +0.03 (p 0.915, n 18). fragile.
- cell type
- strongest in microglia: -0.65 (p 0.0034, n 18) vs +0.03 in dopamine neurons. proposing microglia.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CASP8 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up CASP8 · microglia · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.30 p 0.286 (needs p < 3.1e-4)
Receipts
loading the receipts